---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-017059"
form_type: "8-K"
ticker: null
cik: "0001029125"
company_name: "Panbela Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:29:27.493209+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Panbela Q1 net loss $7.1M; ASPIRE trial interim analysis delayed to Q1 2025 due to lower event rate

## Summary
- ASPIRE trial interim OS analysis delayed to Q1 2025; lower-than-expected event rate may signal improved survival.
- ASPIRE enrollment >50%; complete enrollment of ~600 patients expected by Q1 2025.
- Q1 2024 R&D expenses $5.5M (up from $3.5M YoY) driven by ASPIRE expansion; net loss per share $2.28.
- Cash $262k as of March 31; closed $9.0M public offering in January; $0.8M nondilutive payment from US WorldMeds in April.
- Stock moved to OTCQB; new US and Canada patent for eflornithine/sulindac fixed dose combination.

## SEC filing metadata
- accession: 0001437749-24-017059
- form_type: 8-K
- cik: 0001029125
- company_name: Panbela Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1029125/000143774924017059/0001437749-24-017059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1029125/000143774924017059/pbla20240514_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-017059
- JSON: https://secwatch.observer/filing/0001437749-24-017059.json
- Plain text: https://secwatch.observer/filing/0001437749-24-017059.txt

## Key facts
- Earnings Releases
  Panbela Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss in the quarter was approximately $7.1 million, or $2.28 per diluted share, EPS $2.28 per diluted share.
  - Period: the quarter ended March 31, 2024
  - Net income: Net loss in the quarter was approximately $7.1 million, or $2.28 per diluted share
  - EPS: $2.28 per diluted share
  - Result: reported results
  source text: Net loss in the quarter was approximately $7.1 million, or $2.28 per diluted share, compared to a net loss of $5.1 million, or $392.76 per diluted share, in the same period last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774924017059/0001437749-24-017059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.